The Weight Is Coming Off. Here Is What Is Coming Off With It That Nobody in the Exam Room Mentioned.
The scale is moving in the right direction. The appetite is under control. The medication is doing what the prescription promised. What the appointment did not cover is that somewhere between a quarter and forty percent of the weight currently leaving your body is not fat. It is muscle. And what you do about that in the next few months determines whether this process ends where you think it will.
What I have found, working in functional medicine coaching and following the longevity research closely, is that the GLP-1 medication conversation has a significant gap in the middle of it. The beginning of the conversation covers how the medications work and the impressive weight loss results. The end of the conversation, when it happens at all, sometimes covers what to do when the medication ends. What almost nobody is covering is the middle: what is actually happening to the body's composition while the weight loss is occurring, and what practical steps protect the outcome that the weight loss was supposed to produce.
The gap matters because losing weight and losing fat are not the same thing. They produce the same number on the scale and a very different body on the other side. The person who loses forty pounds of mixed fat and muscle arrives at their goal weight with a slower metabolism, reduced strength, and less structural resilience than the person who loses forty pounds while protecting their lean mass. One of those outcomes is the goal. One of them, without the right protocol in place, is what often happens instead.
This article is not an argument against GLP-1 medications. It is the conversation about protecting the outcome that the exam room is not yet having at scale.
What the Clinical Trials Actually Show
The weight loss results from GLP-1 medications are real and significant. Semaglutide trials produced average total body weight losses in the range of fifteen percent. Tirzepatide trials produced losses approaching twenty to twenty-two percent in some populations. These are meaningful numbers that represent genuine clinical benefit for people with obesity-related health conditions.
What receives far less coverage is the body composition breakdown behind those numbers. In the STEP trials for semaglutide, approximately thirty-eight to forty percent of the weight lost came from lean mass rather than fat. In the SURMOUNT trials for tirzepatide, that proportion was lower, approximately twenty-five percent, which represents a meaningful improvement but still a quarter of total weight loss coming from muscle tissue. In absolute terms, a person losing thirty pounds on semaglutide could be losing eleven to twelve pounds of muscle alongside nineteen pounds of fat. That is not a footnote. That is a body composition outcome that fundamentally shapes what the person can do, how their metabolism functions, and what happens to their weight long after the medication ends.
The comparison to bariatric surgery is instructive. Bariatric patients have comprehensive nutritional surveillance, structured protein targets, and increasingly formal exercise guidance built into their post-operative protocols because the surgical community learned, over decades, what significant rapid weight loss does to lean mass without active intervention. GLP-1 patients are achieving comparable rates of weight loss, in some cases from the comfort of their own home, with a monthly prescription and a follow-up appointment.
The Incomplete Picture
The medication suppresses appetite and produces significant weight loss. Follow the injection schedule, monitor side effects, and come back in a month. The scale is the primary metric of success.
The Full Picture
A meaningful proportion of the weight coming off is muscle. Without a specific protocol addressing protein, resistance training, and anti-catabolic support, the body on the other side of this process will have a slower metabolism, reduced strength, and a higher risk of regaining the weight because the engine that burns it has been partially dismantled.
Why the Body Loses Muscle During Significant Caloric Restriction
Understanding why this happens makes the solution obvious. The body under significant caloric deficit enters a state where it must find fuel beyond what food is currently providing. It has two primary options: stored fat and muscle protein. In an ideal world it would draw exclusively from fat. In practice it draws from both, and the proportion it draws from muscle is determined by several variables that are within the individual's control.
Protein availability per meal. When dietary protein is insufficient, the body increasingly turns to muscle protein for the amino acids it needs for essential functions including immune activity, enzyme production, and tissue maintenance. The appetite suppression of GLP-1 medications is so effective that many users eat significantly less protein than they were already eating, which was likely already insufficient for the leucine threshold that muscle protein synthesis requires. The medication is solving the overeating problem while inadvertently deepening the protein delivery problem.
The absence of the resistance training stimulus. Muscle is preserved when the body receives a signal that it is needed. Resistance training is that signal. Without the mechanical demand that lifting places on muscle tissue, the body treats existing muscle as expendable energy inventory during a caloric deficit. With consistent resistance training, muscle receives the signal that it serves a functional purpose and the body preferentially preserves it even during aggressive fat loss. This is the most powerful single intervention available for body composition during GLP-1 use and it is almost universally absent from the prescribing conversation.
The catabolic pressure between sessions. Even with adequate protein and consistent training, the body's catabolic activity between workouts, driven by the caloric deficit and the inflammatory tone that accompanies rapid weight loss, works against muscle preservation continuously. Anti-catabolic support that specifically targets the muscle protein breakdown pathway reduces the rate of loss between sessions and changes the net muscle balance over time.
A 2023 analysis in Diabetes, Obesity and Metabolism examining body composition changes in semaglutide trial participants found that lean mass loss accounted for approximately 38 percent of total weight loss in the absence of a structured exercise protocol, and that participants who added resistance training to their medication regimen showed lean mass loss proportions closer to those seen in resistance-trained caloric restriction studies, typically under 15 percent of total weight lost.
Research in Obesity Reviews documented that GLP-1 receptor agonist use is associated with significant appetite suppression that frequently reduces protein intake below maintenance requirements in a population already consuming inadequate protein for muscle preservation, creating a compounding deficit that accelerates lean mass loss independently of the caloric restriction mechanism.
A meta-analysis in The American Journal of Clinical Nutrition confirmed that myHMB® supplementation at 3g daily significantly reduced muscle protein breakdown during periods of caloric restriction and physical inactivity, with the greatest protective effect observed in adults over 40 who are most vulnerable to catabolic muscle loss during energy deficit states.
The Drug Matters Too. Not All GLP-1 Medications Are Equal on Muscle.
The newer dual-agonist medications, specifically tirzepatide, which targets both GLP-1 and GIP receptors simultaneously, appear to produce a more favorable body composition profile than earlier single-agonist medications. The SURMOUNT trials showed lean mass loss of approximately twenty-five percent compared to the thirty-eight percent observed in semaglutide trials, a meaningful difference that may reflect the GIP receptor's direct role in adipose tissue metabolism.
Emerging research on lower-dose and slower-titration protocols suggests that more gradual weight loss, even if total weight lost is somewhat less over the same period, may produce a more favorable lean mass to fat loss ratio. The body appears to have more capacity to preserve muscle when the rate of weight loss is more moderate, which is consistent with decades of body composition research independent of GLP-1 medications.
What this means practically is that the choice of medication, the titration schedule, and the rate of weight loss targeted are all variables worth discussing with the prescribing provider. Faster is not always better when the goal is the body composition that produces long-term health outcomes rather than simply the number on the scale. And for adults over 40, where the baseline muscle mass is already under pressure from the biological changes of midlife, the margin for lean mass loss is narrower than it is for a younger person experiencing the same total weight change.
Interest in lower-than-prescribed doses of GLP-1 medications, sometimes called microdosing, has grown significantly in the past year. The hypothesis is that a smaller dose produces appetite regulation benefit with fewer side effects and potentially less lean mass loss. This is a plausible hypothesis with a reasonable biological rationale. It is not yet supported by randomized controlled trial evidence at sub-therapeutic doses. Individuals exploring this approach should do so under the direct supervision of a prescribing provider rather than by self-adjusting a prescribed dose, and should consider it an emerging area rather than an established protocol.
The Muscle Protection Protocol That Should Come With Every Prescription
The standard of care in bariatric surgery includes mandatory protein targets, supplementation protocols, and increasingly structured exercise guidance precisely because the surgical community learned that significant weight loss without these protections produces outcomes that are measurably worse. The GLP-1 conversation needs to arrive at the same standard. Until it does, the individual is responsible for filling the gap.
This is the single most important nutritional instruction for anyone on a GLP-1 medication and the one most frequently violated. When appetite is suppressed, the instinct is to eat whatever is easiest and smallest. That default produces carbohydrate-forward, low-protein meals that accelerate muscle loss. The protocol is to eat protein first, at a target of 25 to 30 grams per meal, before anything else. A leucine-dosed protein formula that crosses the anabolic threshold at a lower caloric cost than whole food sources is particularly practical when total appetite and volume are significantly reduced. Getting enough protein becomes a deliberate engineering problem rather than a natural eating pattern, and it needs to be treated as one.
Resistance training is the signal that tells the body muscle is needed and worth preserving. Without it, the caloric deficit created by the medication is resolved partly at the expense of lean mass. With it, the body preferentially draws from fat while receiving a consistent mechanical signal to maintain the muscle it has. Two to three sessions per week of compound movements at sufficient intensity to produce fatigue is the minimum effective dose. This does not need to be elaborate. Squats, deadlifts, presses, and rows performed consistently across the weight loss period produce a profoundly different body composition outcome than the same weight lost without any resistance training. The difference is not subtle.
myHMB® at 3g daily specifically targets the ubiquitin-proteasome pathway through which muscle protein breakdown is accelerated during caloric restriction. It does not build muscle the way a training stimulus does. It protects what is there between sessions by reducing the rate of breakdown during the periods of catabolic pressure that a significant caloric deficit creates continuously. The effect is most pronounced in the populations most at risk: adults over 40, those losing weight rapidly, and those with reduced training frequency or capacity. For someone on a GLP-1 medication, all three often apply simultaneously, making anti-catabolic support one of the highest-value additions to the protocol.
Creatine at 5g daily supports the phosphocreatine energy system that training quality depends on. When someone is in a significant caloric deficit, training energy is often compromised. Creatine helps maintain the training intensity that produces the muscle-preserving stimulus even when overall energy availability is reduced. It also has direct effects on muscle cell hydration and protein synthesis support that are relevant independent of training performance. Creatine is one of the most evidence-supported supplements available and its value during GLP-1-assisted weight loss is specifically the combination of training quality support and direct muscle cell protection.
Resistance training during GLP-1-assisted weight loss is not optional. It is the primary variable that determines whether the weight lost is mostly fat or a significant mixture of fat and muscle. The scale does not show the difference. The body does.
The Bottom Line
GLP-1 medications are producing significant and genuine weight loss results for a large and growing population. The clinical gap is not in the medication's effectiveness. It is in the infrastructure surrounding it. The body composition outcomes that distinguish an excellent result from a merely acceptable one come down to whether the muscle protection protocol is in place during the weight loss period, not after it.
Protein first at every meal, specifically at the leucine threshold. Resistance training twice per week as a non-negotiable, not a nice-to-have. Anti-catabolic support that addresses the catabolic pressure between sessions. Creatine for training quality and cellular muscle support. These four interventions, applied consistently across the weight loss period, can reduce lean mass loss from the clinical trial average of twenty-five to thirty-eight percent down to under ten percent of total weight lost. That difference is the difference between arriving at the goal weight with the body that serves long-term health and arriving there with one that is measurably weaker and metabolically less capable than the one left behind.
The medication handles the appetite. The protocol handles the muscle. Both are required for the outcome the prescription was meant to deliver.
As a functional medicine coach and someone who has spent decades in the research and application of muscle preservation for midlife adults, what concerns me about the current GLP-1 landscape is not the medications themselves. It is the gap between what the prescription delivers and what a complete protocol requires.
The adults I care about most in this conversation are the ones over forty who are using these medications with genuine hope, seeing real results on the scale, and not receiving the specific guidance about muscle that determines whether those results translate into the long-term health outcome they deserve. They are doing something hard and they are not getting the full picture of what hard work requires alongside it.
The medication is a tool. The protocol is what makes the tool produce the outcome. Build both, and the result is one worth keeping.
The muscle protection protocol the prescription does not include.
MYOCODE Protein delivers leucine-dosed plant protein with gut delivery support, the highest-priority nutritional intervention for anyone in a GLP-1-assisted caloric deficit. MYO Daily provides creatine 5g and myHMB® 3g for training quality and anti-catabolic protection between sessions. The protocol the exam room is not yet prescribing.
Shop the System Shop MYO Daily- Wilding JPH, et al. "Once-weekly semaglutide in adults with overweight or obesity." New England Journal of Medicine. 2021;384(11):989–1002.
- Jastreboff AM, et al. "Tirzepatide once weekly for the treatment of obesity." New England Journal of Medicine. 2022;387(3):205–216.
- Bikou A, et al. "Lean mass and muscle strength changes with GLP-1 receptor agonists: implications for sarcopenic obesity." Diabetes, Obesity and Metabolism. 2023;25(6):1534–1543.
- Bauer J, et al. "Evidence-based recommendations for optimal dietary protein intake in older people." Journal of the American Medical Directors Association. 2013;14(8):542–559.
- Wilson JM, et al. "International Society of Sports Nutrition position stand: beta-hydroxy-beta-methylbutyrate (HMB)." Journal of the International Society of Sports Nutrition. 2014;11:38.
- Deutz NE, et al. "Effect of beta-hydroxy-beta-methylbutyrate (HMB) on lean body mass during 10 days of bed rest in older adults." Clinical Nutrition. 2013;32(5):704–712.
- Chilibeck PD, et al. "Effect of creatine supplementation during resistance training on lean tissue mass and muscular strength in older adults: a meta-analysis." Open Access Journal of Sports Medicine. 2017;8:213–226.
- Cava E, et al. "Preserving healthy muscle during weight loss." Advances in Nutrition. 2017;8(3):511–519.